Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461909 | 0.90 | TAAR1 (0.39) | PTGS2CYP2C19CYP3A4PTGS1SMN1; SMN2 | |
| SCHEMBL4461901 | 0.88 | CYP3A4 (0.52) | PTGS2CYP3A4PTGS1ALDH1A1CYP3A5 | |
| SCHEMBL4456792 | 0.85 | CYP3A4 (0.44) | PTGS2CYP3A4PTGS1PDE4BCYP3A5 | |
| SCHEMBL4458284 | 0.85 | PTGS2 (0.44) | PTGS2CYP3A4PTGS1PDE4APDE4B | |
| SCHEMBL4462110 | 0.84 | CYP2C19 (0.37) | PTGS2CYP2C19CYP3A4PTGS1SMN1; SMN2 | |
| SCHEMBL4461686 | 0.83 | CYP2A6 (0.46) | CYP2C19SMN1; SMN2ALDH1A1CYP2A6MAPT | |
| SCHEMBL4458277 | 0.82 | CYP2C19 (0.33) | PTGS2CYP2C19CYP3A4PTGS1SMN1; SMN2 | |
| SCHEMBL4458988 | 0.81 | CYP2A6 (0.39) | CYP2C19ALDH1A1CYP2A6MAPT | |
| SCHEMBL4472068 | 0.81 | TAAR1 (0.39) | PTGS2CYP3A4PTGS1PDE4BCYP3A5 | |
| SCHEMBL4460448 | 0.80 | CYP3A4 (0.44) | PTGS2CYP3A4PTGS1ALDH1A1CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | claimed |
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| EP-1981507-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | PTGS2 3086/4885CYP2C19 2828/4885CYP3A4 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.